Chronic afterload reduction in infants and children with primary myocardial disease

Area of Science:

• Pediatric Cardiology
• Cardiovascular Pharmacology

Background:

• Primary myocardial disease (PMD) in children presents significant management challenges.
• Effective long-term therapeutic strategies for pediatric PMD are crucial.

Purpose of the Study:

• To evaluate the long-term effects of oral hydralazine for chronic afterload reduction in pediatric patients with PMD.
• To assess hydralazine's impact on cardiac function and ventricular remodeling.

Main Methods:

• Twenty-six children (3-48 months) with confirmed PMD received standard care (digitalis, diuretics).
• Fourteen patients also received oral hydralazine (up to 4.0 mg/kg/day).
• Echocardiographic assessments were performed regularly, with long-term follow-up data available for 10 hydralazine and 8 control patients.

Main Results:

• Hydralazine group showed significant improvement: increased shortening fraction (14.5% to 23.2%, P<0.01).
• Reduced pre-ejection period to ejection time ratio (0.52 to 0.35, P<0.001) and normalized left ventricular size (116 to 87, P<0.01).
• Control group showed no significant changes.

Conclusions:

• Hydralazine therapy is an effective adjunct for managing primary myocardial disease in infants and children.
• Chronic afterload reduction with hydralazine improves cardiac performance and ventricular dimensions in pediatric PMD.
• Significant echocardiographic improvements were observed after 12 months of hydralazine treatment.